Neurogene (NASDAQ:NGNE) Earns Outperform Rating from Analysts at Lifesci Capital

Equities researchers at Lifesci Capital started coverage on shares of Neurogene (NASDAQ:NGNE) in a report issued on Monday,Benzinga reports. The brokerage set an “outperform” rating and a $50.00 price target on the stock. Lifesci Capital’s price objective indicates a potential upside of 169.88% from the stock’s current price.

Several other research firms have also commented on NGNE. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Neurogene in a research report on Tuesday, January 13th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Price Performance

NGNE stock opened at $18.53 on Monday. Neurogene has a 1-year low of $6.88 and a 1-year high of $37.27. The business has a 50 day simple moving average of $19.78 and a two-hundred day simple moving average of $22.04. The company has a market capitalization of $286.98 million, a price-to-earnings ratio of -4.52 and a beta of 1.60.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.27. Sell-side analysts anticipate that Neurogene will post -4.27 EPS for the current fiscal year.

Institutional Trading of Neurogene

Several large investors have recently bought and sold shares of NGNE. BNP Paribas Financial Markets grew its holdings in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after buying an additional 978 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after acquiring an additional 1,232 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after buying an additional 1,059 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in Neurogene in the third quarter valued at approximately $187,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Neurogene in the third quarter valued at $223,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.